Neutropenia News and Research RSS Feed - Neutropenia News and Research

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.
New oral breast cancer drug has potential to combat other types of cancer

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology. [More]
Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Combination therapy can help overcome endocrine resistance in women with advanced breast cancer

Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer. [More]
Post-progression afatinib exposure boosts NSCLC outcomes

Post-progression afatinib exposure boosts NSCLC outcomes

Continued exposure to afatinib plus paclitaxel can benefit non-small-cell lung cancer patients who developed resistance to erlotinib or gefitinib and progressed after initially responding to afatinib monotherapy, suggest phase III trial results. [More]
Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. [More]
Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Palbociclib and paclitaxel combination shrinks tumors in patient with ER positive breast cancer

Combining the new breast cancer drug palbociclib with paclitaxel (Taxol) shrank tumors in nearly half of patient with estrogen-receptor (ER) positive breast cancer, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL). [More]
Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma. [More]
Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL). [More]
Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

The combination of ibrutinib and rituximab shows activity in patients with relapsed or refractory mantle cell lymphoma, suggests research published in The Lancet Oncology. [More]
Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia. [More]
Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo. [More]
FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. [More]
Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. [More]
Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer. [More]
Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer. [More]
FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). [More]
New combination treatment approved by FDA for metastatic pancreatic cancer

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. [More]
FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies. [More]
Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Advertisement
Advertisement